Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Zurich
This research in highlanders with HAPH diagnosed by echocardiography and defined by a RV/RA \>30 mmHg who permanently live at HA \>2500 m will have nocturnal respiratory sleep studies near their living altitude in Aksay at 3200 m and on night 1 and 6 at 760m after relocation.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Permanently living \>2500 m
HAPH diagnosed with a minimum RV/RA of 30 mmHg assessed by echocardiography at an altitude of 3200 m
Written informed consent
You may not be if
Highlanders who cannot follow the study investigations,
Patients with moderate to severe concomitant lung disease (FEV1\<70% or forced vital capacity \<70%), severe parenchymal lung disease, heavy smoking \>20 cigarettes/day or \>20 pack-years.
Coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months
Regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)
Clareo Health | High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), SDB Assessed at HA (3200 m) vs LA (760 m)
